Farallon Capital Management LLC Has $90.36 Million Stock Holdings in Tango Therapeutics, Inc. $TNGX

Farallon Capital Management LLC lifted its position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) by 17.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,757,000 shares of the company’s stock after purchasing an additional 1,600,000 shares during the quarter. Farallon Capital Management LLC owned 0.08% of Tango Therapeutics worth $90,359,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in TNGX. Legal & General Group Plc increased its position in shares of Tango Therapeutics by 30.7% in the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after buying an additional 1,640 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Tango Therapeutics by 44.3% during the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock worth $49,000 after acquiring an additional 2,907 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Tango Therapeutics by 78.8% during the second quarter. Ameritas Investment Partners Inc. now owns 7,830 shares of the company’s stock worth $40,000 after acquiring an additional 3,452 shares in the last quarter. ProShare Advisors LLC grew its stake in Tango Therapeutics by 30.1% in the second quarter. ProShare Advisors LLC now owns 19,775 shares of the company’s stock valued at $101,000 after acquiring an additional 4,570 shares during the period. Finally, Intech Investment Management LLC grew its stake in Tango Therapeutics by 13.7% in the second quarter. Intech Investment Management LLC now owns 45,675 shares of the company’s stock valued at $234,000 after acquiring an additional 5,518 shares during the period. Institutional investors and hedge funds own 78.99% of the company’s stock.

Insider Activity at Tango Therapeutics

In other news, insider Adam Crystal sold 20,251 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $15.00, for a total transaction of $303,765.00. Following the completion of the transaction, the insider directly owned 112,622 shares of the company’s stock, valued at $1,689,330. This trade represents a 15.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Daniella Beckman sold 10,317 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $126,486.42. Following the transaction, the chief financial officer directly owned 184,297 shares of the company’s stock, valued at $2,259,481.22. This represents a 5.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 133,884 shares of company stock valued at $1,724,622. 7.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TNGX has been the topic of a number of research analyst reports. Wedbush raised their price target on Tango Therapeutics from $15.00 to $19.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Piper Sandler boosted their price objective on Tango Therapeutics from $11.00 to $14.00 and gave the company an “overweight” rating in a research report on Friday, January 16th. Mizuho increased their target price on Tango Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 11th. Wolfe Research began coverage on shares of Tango Therapeutics in a report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tango Therapeutics in a research note on Wednesday, January 21st. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Tango Therapeutics Price Performance

TNGX opened at $17.30 on Monday. The business’s 50-day moving average price is $12.67 and its two-hundred day moving average price is $9.83. Tango Therapeutics, Inc. has a 1 year low of $1.03 and a 1 year high of $17.63. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of -19.88 and a beta of 1.76.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. Sell-side analysts anticipate that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.